Novo Nordisk ​said on ‌Monday its ​next-generation ​experimental drug had ⁠achieved ​an estimated ​average weight loss of ​12.4% ​in a late-stage ‌trial ⁠and that it ​was ​superior ⁠to Eli ​Lilly's ​drug.